News & Events

IMPEL NEUROPHARMA ANNOUNCES FDA SUBMISSION OF NEW DRUG APPLICATION FOR INP104 FOR THE ACUTE TREATMENT OF MIGRAINE

~The INP104 New Drug Application is Supported by Results from the Phase 3 STOP 301 Study~ ~Dihydroergotamine mesylate (DHE) is Administered via Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper…

IMPEL NEUROPHARMA PRESENTS DATA FROM PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE AT 2020 MIGRAINE TRUST VIRTUAL SYMPOSIUM

66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel’s Proprietary Precision Olfactory…

IMPEL NEUROPHARMA ANNOUNCES PUBLICATION OF POSITIVE RESULTS OF SNAP 101 STUDY FOR INP105 FOR THE TREATMENT OF ACUTE AGITATION IN THE JOURNAL OF CLINICAL PSYCHIATRY

Study Shows INP105 Achieves Rapid Absorption Which May Provide An Effective, Convenient, & Noninvasive Future Alternative for Treating Acute Agitation In the Home, Community, or Hospital Setting INP105 is a Powder Formulation of Olanzapine, the Gold Standard Treatment for Acute…

2 3 4